Financial Report: Patheon

Patheon

4Q Revenues: $510 million (+10%)

4Q Earnings: $44.1 million (earnings were $147.4 million 4Q15)

FY Revenues: $1.9 billion (+5%)

FY Earnings: $31.7 million (earnings were $138.4 million FY15)

Comments: Despite temporary closures at two sites, the DPS segment sales were $298 million with continued volume growth and demand across sterile and oral solid dose forms. PDS sales were $60 million, primarily driven by strong demand for sterile and low-solubility services. The Drug Substance segment sales were $152 million with continued strong demand for biologics services, which now represents approximately 50% of segment revenues.